0700 10992 Book a consultation

05 august 2026

Transvaginal Radiofrequency Ablation: Minimally Invasive Treatment for Uterine Fibroids

Uterine fibroids, also known as myomas or leiomyomas, are benign growths that develop from the muscle tissue of the uterus. Although they are not cancerous, fibroids can significantly affect a woman's quality of life by causing heavy or prolonged menstrual bleeding, anaemia, pelvic pain, abdominal pressure and, in some cases, fertility problems.

For women who wish to avoid conventional surgery and preserve their uterus, transvaginal radiofrequency ablation — TVRFA may offer a minimally invasive treatment option.

At Adella Fertility, each patient is carefully assessed to determine whether TVRFA is suitable for her symptoms, the characteristics of her fibroids and her future reproductive plans.

What is transvaginal radiofrequency ablation?

TVRFA is an ultrasound-guided procedure that uses controlled radiofrequency energy to treat uterine fibroids from the inside — from within the fibroid itself.

A thin radiofrequency electrode is inserted through the natural vaginal route and positioned directly in the body of the fibroid under continuous ultrasound guidance. Controlled thermal energy is then delivered to the target tissue, causing thermal necrosis while aiming to preserve the surrounding healthy myometrium.

Over the following months, the treated tissue is gradually reabsorbed by the body, leading to a progressive reduction in fibroid volume and related symptoms. The technique was developed and standardised for the transvaginal treatment of fibroids by Dr. Victoria Rey in Spain.

How is the procedure performed?

The TVRFA process can be described in four main stages:

  1. Visualisation

The doctor uses transvaginal ultrasound to identify the fibroid, assess its location and determine the safest approach.

  1. Targeting

A specialised radiofrequency electrode is carefully inserted into the fibroid under real-time ultrasound guidance.

  1. Treatment

Radiofrequency energy is delivered precisely to different zones of the fibroid. The “moving-shot” technique (with successive repositioning) may be used to treat the target volume gradually and accurately.

  1. Result

After the procedure, the treated fibroid gradually shrinks. Symptoms such as heavy menstrual bleeding, pelvic discomfort and pressure may improve over time.

The VIVA radiofrequency system described in the clinical materials includes a dedicated transvaginal RFA mode, impedance control, electrode calibration checks and a built-in electrode cooling system.

What are the potential benefits of TVRFA?

Compared with traditional surgical approaches, TVRFA may offer several advantages for appropriately selected patients:

  • no abdominal incisions;
  • no surgical removal of the uterus;
  • preservation of the surrounding healthy uterine tissue;
  • no surgical sutures in the uterine wall;
  • a short, outpatient procedure;
  • faster recovery compared with conventional surgery;
  • gradual reduction in fibroid volume and symptoms;
  • a potential uterus-preserving option for women considering future pregnancy.

Because the procedure is performed through the natural vaginal route, it does not require abdominal access. Published descriptions characterise TVRFA as a short outpatient intervention performed under sedation, preserving the surrounding myometrium and leaving no residual surgical scar.

However, no treatment is suitable for every patient. The benefits, risks and alternatives should always be discussed with a specialist before a decision is made.

Who may be a suitable candidate?

TVRFA may be considered for women who:

  • have symptomatic uterine fibroids;
  • experience heavy menstrual bleeding, pelvic pain or pressure;
  • wish to preserve their uterus;
  • want to avoid or postpone conventional surgery;
  • are considering pregnancy in the future;
  • have fibroids that can be reached and safely treated via the transvaginal approach.

The number, size, type and location of the fibroids must be assessed through a detailed gynaecological examination and high-resolution ultrasound. In certain cases, additional imaging or other tests may be recommended.

The final treatment plan is always individualised according to the patient's symptoms, medical history and reproductive goals.

TVRFA and future pregnancy

Preserving the uterus is particularly important for women who would like to become pregnant. Because TVRFA treats the fibroid without cutting or suturing the uterine wall, it aims to preserve the structure of the surrounding myometrium.

A 2025 retrospective study evaluated 226 patients who became pregnant after transvaginal radiofrequency ablation. The median reduction in fibroid volume was 49.4% at six months and 69.8% at 12 months. Of these pregnancies, 34.5% occurred spontaneously and 65.5% were achieved through assisted reproductive technologies.

The study reported no cases of uterine rupture, placental abruption or foetal growth restriction. Pregnancy outcomes were considered comparable to those observed in the general population.

These results are encouraging but require careful interpretation. The study included patients who had already achieved pregnancy, so it does not establish the overall likelihood of becoming pregnant after TVRFA. It is also retrospective rather than a randomised comparison between TVRFA and other fibroid treatments. The authors note that larger fibroids were associated with a longer time to pregnancy and that shorter intervals between treatment and conception were associated with a higher miscarriage rate.

For this reason, the right time to start trying to conceive or to proceed with fertility treatment should be determined individually by the treating doctor.

What happens after the procedure?

After TVRFA, the fibroid does not disappear immediately. The treated tissue gradually shrinks as it is naturally reabsorbed by the body.

Follow-up visits and ultrasound examinations allow the medical team to assess:

  • the reduction in fibroid volume;
  • changes in menstrual bleeding;
  • improvement in pain or pelvic pressure;
  • the recovery of the uterine tissue;
  • the right time for future fertility treatment or pregnancy.

Clinical studies report a progressive reduction in fibroid volume and improvement in symptoms during follow-up after transvaginal radiofrequency ablation.

A personalised approach at Adella Fertility

Choosing the right treatment for uterine fibroids requires a complete and individual assessment. At Adella Fertility, our specialists evaluate each patient's symptoms, ultrasound findings, medical history and fertility plans before recommending the most appropriate therapeutic approach.

Book a consultation with the Adella Fertility team in Sofia to find out whether transvaginal radiofrequency ablation may be right for you.

References

  1. Rey VE, Falcon MM, Ferrara I, Yanes G. Pregnancy Outcomes After Transvaginal Radiofrequency Ablation of Leiomyomas. Obstetrics & Gynecology. 2025;145(3):346-353. doi:10.1097/AOG.0000000000005826.
  1. Rey VE, Labrador R, Falcon M, Garcia-Benitez JL. Transvaginal Radiofrequency Ablation of Myomas: Technique, Outcomes, and Complications. Journal of Laparoendoscopic & Advanced Surgical Techniques. 2019;29(1):24-28. doi:10.1089/lap.2018.0293.
  1. Fasciani A, Turtulici G, Siri G, Ferrero S, Sirito R. A Prospective Intervention Trial on Tailored Radiofrequency Ablation of Uterine Myomas. Medicina. 2020;56(3):122. doi:10.3390/medicina56030122.
  1. Clínica Victoria Rey. Tratamiento de miomas por radiofrecuencia VRey® sin cirugía. Accessed July 29, 2026.

Need help?